Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816].
Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816].
复制标题
DOI：
10.1186/1472-6882-4-12
复制
发表时间：
2004-09-02
影响因子：
--
通讯作者：
Khalighi-Cigaroudi, Farahnaz
中科院分区：
文献类型：
--
作者：
Akhondzadeh, Shahin;Fallah-Pour, Hasan;Khalighi-Cigaroudi, Farahnaz
背景：与抑郁症相关的发病率和死亡率是相当可观的，并继续增加。抑郁症目前在全世界残疾的主要原因中排名第四，仅次于下呼吸道感染、产前条件和艾滋病毒/艾滋病。番红花用于治疗抑郁症。许多药用植物教科书都提到了这一适应症，但没有循证文件。我们的目的是比较的疗效的藏红花（番红花）与丙咪嗪在治疗轻度至中度抑郁症在一个为期6周的试点双盲randomized trial.METHODS：30名成年门诊患者谁符合诊断和统计手册的精神障碍，第4版的基础上，结构化的临床采访DSM IV的抑郁症参加了试验的柱头。患者基线汉密尔顿抑郁量表评分至少为18分。在这项双盲、单中心试验中，患者被随机分配接受藏红花胶囊30 mg/天（TDS）（组1）和丙咪嗪胶囊100 mg/天（TDS）（组2），为期6周的研究。= 1，P = 0.09）。在丙咪嗪组的抗胆碱能作用，如口干，也镇静观察到更多的时候，这是predicted.CONCLUSION：主要的总体发现，从这项研究是，阿司他丁龙可能是治疗轻中度抑郁症的治疗效益。据我们所知，这是第一个支持该适应症的临床试验。一个大规模的安慰剂对照试验是必要的。
BACKGROUND: The morbidity and mortality associated with depression are considerable and continue to increase. Depression currently ranks fourth among the major causes of disability worldwide, after lower respiratory infections, prenatal conditions, and HIV/AIDS. Crocus sativus L. is used to treat depression. Many medicinal plants textbooks refer to this indication whereas there is no evidence-based document. Our objective was to compare the efficacy of stigmas of Crocus sativus (saffron) with imipramine in the treatment of mild to moderate depression in a 6-week pilot double-blind randomized trial.METHODS: Thirty adult outpatients who met the Diagnostic and Statistical Manual of Mental Disorders, 4th edition for major depression based on the structured clinical interview for DSM IV participated in the trial. Patients have a baseline Hamilton Rating Scale for Depression score of at least 18. In this double-blind, single-center trial, patients were randomly assigned to receive capsule of saffron 30 mg/day (TDS) (Group 1) and capsule of imipramine 100 mg/day (TDS) (Group 2) for a 6-week study.RESULTS: Saffron at this dose was found to be effective similar to imipramine in the treatment of mild to moderate depression (F = 2.91, d.f. = 1, P = 0.09). In the imipramine group anticholinergic effects such as dry mouth and also sedation were observed more often that was predictable.CONCLUSION: The main overall finding from this study is that saffron may be of therapeutic benefit in the treatment of mild to moderate depression. To the best of our knowledge this is the first clinical trial that supports this indication for saffron. A large-scale trial with placebo control is warranted.